For millions of patients living with autoimmune diseases, ai3Bio is working to move care beyond management toward lasting remission, and now it has $48.0M in Series A funding to advance that mission. The biotech company secured the capital from investors including UPMC Enterprises, Ziff Capital Partners, Cockrell Interests, LLC, and Tanis Ventures.
ai3Bio's approach involves resetting the immune system at its root, utilizing its proprietary STARx and T Deplete platforms which combine AI discovery with technology engineered to directly target and eliminate disease-causing Th17 cells in a single step.
